LENZ Therapeutics (LENZ) Projected to Post Quarterly Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ) is projected to issue its quarterly earnings data before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.

LENZ Therapeutics (NASDAQ:LENZ) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.09. During the same period in the prior year, the firm earned ($1.33) EPS. On average, analysts expect LENZ Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

LENZ Therapeutics Stock Down 0.6 %

LENZ Therapeutics stock opened at $25.37 on Tuesday. LENZ Therapeutics has a 12-month low of $14.42 and a 12-month high of $38.93. The stock has a 50-day simple moving average of $29.49 and a 200 day simple moving average of $26.81.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $38.00 target price on shares of LENZ Therapeutics in a research report on Thursday, November 7th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, LENZ Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $35.40.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.